[Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].

Clicks: 288
ID: 12022
2003
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #2 of 9 articles by views in klinicheskaia meditsina

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The efficiency of antihelicobacter therapy was evaluated in 36 and 22 patients from experimental and control groups, respectively. In the control group, antihelicobacter agents were given in usual doses in the control group and in the experimental one; they were used in doses depending on the level of Helicobacter pylori (HP) infection of the gastric mucosa (GM). The findings showed that the efficiency of antihelicobacter therapy was much higher in the group of patients taking antihelicobacter agents in a daily dose depending on the level of GM HP infection.
Reference Key
orziev2003levelklinicheskaia Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Orziev, Z M;Nurbaev, F E;Rakhimova, G Sh;
Journal klinicheskaia meditsina
Year 2003
DOI
DOI not found
URL URL not found
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.